Hi, what are you looking for?
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to breakthrough innovations and increased deals involving NASDAQ biotech...
Sankamap Metals Inc. (CSE: SCU) (‘Sankamap’ or the ‘Company’) the Company and its auditor continue to work diligently toward the completion and filing of...
TORONTO, ON / ACCESS Newswire / December 31, 2025 / NextSource Materials Inc. (TSX:NEXT,OTC:NSRCF)(OTCQB:NSRCF) (‘NextSource’ or the ‘Company’) is pleased to announce the results...
Jeffrey Christian, managing partner at CPM Group, shares his outlook for gold and silver in 2026, explaining why he expects higher prices for the...
Don Durrett: Gold, Silver Price Targets and 15 ‘Must-Own’ Silver Stocks Kicking off the list in the fifth spot is Don Durrett of GoldStockData.com....
The holiday season brings more than festive cheer, as for investors, it may signal the start of the so-called Santa Claus rally. The Santa...
Craig Hemke, publisher of TFMetalsReport.com, shares his thoughts on the gold and silver markets heading into 2026, outlining why he remains bullish. ‘Just keep...
Altius Minerals (TSX:ALS,OTCQX:ATUSF) is making a bet on a lithium market recovery, agreeing to acquire Lithium Royalty (TSX:LIRC) in a C$520 million deal that...
Silverco Mining Ltd. (TSXV: SICO) (‘Silverco’ or the ‘Company’) announces that at the request of CIRO, Silverco wishes to confirm that the Company’s management...
(TheNewswire) December 24th, 2025 TheNewswire – Muskoka, Ontario Steadright Critical Minerals Inc. (CSE: SCM,OTC:SCMNF) (‘Steadright’ or the ‘Company’) Board of Directors has approved...
Trading resumes in: Company: Silverco Mining Ltd. TSX-Venture Symbol: SICO All Issues: Yes Resumption (ET): 9:30 AM CIRO can make a decision to impose...
Correction: The conversion price was incorrectly reported as .14/share. The correct price is .165/share Correction: Nextech3D.ai Provides Shareholder Update on Krafty Labs Acquisition and...
The biotech sector is entering 2026 with a positive outlook, characterized by reasonable valuations, robust oncology momentum and supportive policy tailwinds. This combination is...